$ROTH News! PharmaRoth Labs, Inc. Announces New Distribution Agreement in China
http://www.marketwired.com/press-release/phar...932051.htm
LAS VEGAS, NV--(Marketwired - July 23, 2014) - PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announces a new Distribution Agreement in the country of China. The agreement is with Tianjin Leading Biotechnology Co., Ltd, a leading distributor of traditional Chinese Medicines and Therapies.
"The formula for Sucanon® originated from traditional Chinese medicine, and we are very excited to partner with Tianjin Bio, one of the largest, most respected names in China," stated Luis Lopez, CEO of PharmaRoth. "As a country develops economically, the diet changes dramatically, and modern China has seen tremendous growth rates in metabolic diseases. Still, the Chinese trust and prefer Traditional based therapies over many modern laboratory ones, and we expect Sucanon® to do well in this market as a result of its origins. We have been working on finding the right partner in China for some time, and we are confident that we have done that with Tianjin."
For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at www.pharmaroth.com
About PharmaRoth
PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.
CONTACT INFORMATION
For investor relations contact:
Michael Irving
Paramount Advisors, LLC
(407) 878-5462
http://www.marketwired.com/press-release/phar...932051.htm
LAS VEGAS, NV--(Marketwired - July 23, 2014) - PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announces a new Distribution Agreement in the country of China. The agreement is with Tianjin Leading Biotechnology Co., Ltd, a leading distributor of traditional Chinese Medicines and Therapies.
"The formula for Sucanon® originated from traditional Chinese medicine, and we are very excited to partner with Tianjin Bio, one of the largest, most respected names in China," stated Luis Lopez, CEO of PharmaRoth. "As a country develops economically, the diet changes dramatically, and modern China has seen tremendous growth rates in metabolic diseases. Still, the Chinese trust and prefer Traditional based therapies over many modern laboratory ones, and we expect Sucanon® to do well in this market as a result of its origins. We have been working on finding the right partner in China for some time, and we are confident that we have done that with Tianjin."
For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at www.pharmaroth.com
About PharmaRoth
PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.
CONTACT INFORMATION
For investor relations contact:
Michael Irving
Paramount Advisors, LLC
(407) 878-5462
